Evidence map›Paper›PMID 42096139›Full record

ArticleAnnals of surgical oncology2026

Prognosis After Curative Resection of Esophageal Basaloid Squamous Cell Carcinoma: A Single-Institution Retrospective Study.

Kazuto Harada, Keisuke Kosumi, Hiroki Tsubakihara, Chihiro Matsumoto, Kohei Yamashita, Kojiro Eto, Satoshi Ida, Yuji Miyamoto, Naoya Yoshida, Masaaki Iwatsuki

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kazuto HaradaDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Keisuke KosumiDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Hiroki TsubakiharaDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Chihiro MatsumotoDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Kohei YamashitaDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Kojiro EtoDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Satoshi IdaDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Yuji MiyamotoDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Naoya YoshidaDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
Masaaki IwatsukiDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan. maiwa217@kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0002-0886-4618

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough several studies have described the clinicopathologic features of esophageal basaloid squamous cell carcinoma (EBSCC), its prognosis after curative esophagectomy remains unclear in the modern treatment era.

methodsThis study retrospectively reviewed 803 patients who underwent subtotal esophagectomy at Kumamoto University Hospital between April 2005 and December 2023. Clinicopathologic features of EBSCC, including response to neoadjuvant chemotherapy and survival outcomes, were compared with those of conventional esophageal squamous cell carcinoma (ESCC).

resultsAmong the 803 patients, 33 (4.1 %) had a diagnosis of EBSCC. Of these, 10 EBSCC and 248 ESCC patients received neoadjuvant chemotherapy. None of the EBSCC patients achieved a pathologic response greater than grade 2, whereas 27.8 % of the ESCC patients did (p = 0.01). Recurrence was experienced by for 11 of the 33 EBSCC patients and 218 of the 770 ESCC patients. Hematogenous recurrence was significantly more frequent in EBSCC (82 % vs. 27 %), whereas lymph node recurrence was less common (18 % vs 53 %). Overall survival (OS) was comparable between the groups, with 5-year OS rates of 68.2 % for EBSCC and 70.2 % for ESCC (p = 0.61, log-rank).

conclusionDespite its resistance to neoadjuvant chemotherapy and a higher tendency for hematogenous metastasis, EBSCC exhibits a prognosis comparable with that of ESCC after curative esophagectomy.

Indexed as

Carcinoma, BasosquamousEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyNeoplasm Recurrence, LocalAgedFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeoadjuvant TherapyPrognosisRetrospective StudiesSurvival RateEsophageal basaloid squamous cell carcinomaEsophagectomy

Identifiers

PMID42096139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.